|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Pakistan
Espicom Business Intelligence Ltd, Oct 2011, Pages: 70
THE PHARMACEUTICAL MARKET: PAKISTAN - REVIEW
The macroenvironmental indicators for the Pakistani pharmaceutical market are positive despite economic concerns. Economically, the Economist Intelligence Unit (EIU) projects that Pakistan will be the fourth smallest economy in the Asia Pacific region covered by Espicom in 2016. In GDP per capita terms, Pakistan will rank the second lowest in the Asia Pacific region in 2016. According to the EIU, Pakistan will remain heavily dependent on multilateral institutions and bilateral donors for concessional loans and emergency aid. Demographically, the EIU projects that Pakistan will have the fourth largest population in the Asia Pacific region by 2016. The elderly population represents a very small proportion of the population; it will be the lowest rate in the Asia Pacific region by 2016.
Intellectual property rights (IPR) continue to be a major concern amid patent issues and the prevalence of counterfeit drugs. Despite being a signatory to the WTO TRIPS agreement, Pakistan’s IPR protection for pharmaceuticals is very weak. Pakistan remains on the US Trade Representative’s (USTR) Priority Watch List in 2011. The USTR stated that Pakistan needs to improve the protection against unfair commercial use of pharmaceutical test data, and should establish an effective system to address the patent issues of pharmaceutical products. The Pakistan Medical Association alleges that nearly half of drugs available in the country are counterfeit and that the population spends around three-quarters of their household health budget on drugs, half of which may be fake or unfit for human consumption.
Pakistan’s pharmaceutical market is small and equally split between multinational and domestic companies. Espicom projects the market to grow at a fairly high single-digit CAGR in dollar terms during the forecast period. By 2016, it will be the 11th largest pharmaceutical market in the Asia Pacific region covered by Espicom. The pharmaceutical market in Pakistan is dominated by locally manufactured pharmaceuticals, predominantly generic drugs, which meet around 90% of country’s needs in 2011. Imported retail medicaments account for the remainder of the market, although manufacturers rely heavily on imported raw materials for production. Multinational companies account for around half of the market by value, although local producers have a far greater share in terms of volume.
ENHANCED STRATEGIC INTELLIGENCE
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Customers who bought this item also bought
The Pharmaceutical Market: Indonesia
The Pharmaceutical Market: Canada
The Pharmaceutical Market: Vietnam
The Pharmaceutical Market: Malaysia
The Pharmaceutical Market: Thailand
The Pharmaceutical Market: Taiwan
The Pharmaceutical Market: Turkey
The Pharmaceutical Market: Australia
The Pharmaceutical Market: Greece
The Pharmaceutical Market: Latvia
|
|
|
|
